FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screening Test for Antibodies to Hepatitis C Virus; Guidance for Industry” was released on October 2, 2019 and recommends that CTS modify our current HCV reflex testing algorithm to support these best practices. The new algorithm will take effect on April 20, 2020.
Check out the Communication page for the complete details by clicking the link: Communications
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...